Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
NAV as on 03-04-2025
₹ 32.29
▲1.6%
1D
Inception Returns
22.6%
/yr
Historical NAV & Returns
Absolute
▲
▼
1056 people have invested ₹ 65.1L in Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth in the last three months
About Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund. This fund was started on 11 July, 2019. The fund is managed by Dhaval Shah. The fund could potentially beat inflation in the long-run.
Key Parameters
- Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has ₹755 Cr worth of assets under management (AUM) as on Feb 2025 and is less than category average.
- The fund has an expense ratio 1.1.
Returns
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has given a CAGR return of 22.59% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 12.78%, 19.09% and 25.60% respectively.
Holdings
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Torrent Pharmaceuticals Ltd, Abbott India Ltd, Apollo Hospitals Enterprise Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
Investment objective of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 1000.00 and for SIP is INR 100.00. Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has no lock in period.
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Overview
| Expense ratio | 1.1% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹755 Cr |
| Inception Date | 11 July, 2019 |
| Min Lumpsum/SIP | ₹1000/₹100 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 33.35% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
INDmoney Rank for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
Beats FD returns for both 3Y & 5Y duration
5Y returns in the bottom 25% of the category
3Y returns in the bottom 25% of the category
Trailing Returns
as on (03-Apr-25)
Fund Distribution
as on (28-Feb-25)
Mid cap
43.3%
Large cap
32.5%
Small cap
22.9%
Sector Allocation
Health
99.2%
Basic Materials
0.8%
All changes are between Dec'24 and Feb'25
- AUM of the fund stands at 754.8 Cr as of Feb'25
- AUM decreased by 60.3 Cr between Feb'25 and Jan'25
Top Stocks bought last month
Abbott India Ltd's allocation increased from 2.57% to 6.56%
J.B. Chemicals & Pharmaceuticals Ltd's allocation increased from 2.66% to 3.07%
Sanofi India Ltd's allocation increased from 0.75% to 1.1%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 14.68 % to 14.49 %
Cipla Ltd's allocation decreased from 9.11 % to 8.9 %
Torrent Pharmaceuticals Ltd's allocation decreased from 8.61 % to 7.6 %
Mid Cap allocation has gone up from 37.1% to 43.3%
Large Cap allocation has gone down from 34.8% to 32.5%
Small Cap allocation has gone up from 21.4% to 22.9%
Cash allocation has gone down from 5.7% to 1.4%
Top 2 Sectors in February were Health, Basic Materials
Feb'25
Health
99%
Basic Materials
Jan'25
Health
99%
Basic Materials
Holdings | Weight% | 1M Change | |
|---|---|---|---|
 Sun Pharmaceuticals Industries Ltd | 14.49% | 0% | |
 Cipla Ltd | 8.9% | -5% | |
 Torrent Pharmaceuticals Ltd | 7.6% | -9.3% | |
 Abbott India Ltd | 6.56% | 103.8% | |
 Apollo Hospitals Enterprise Ltd | 5.93% | 0% |
See all
Funds | 1Y Returns | 3Y Returns | 5Y Returns | Since Inception |
|---|---|---|---|---|
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | 12.78% | 19.09% | 25.6% | 22.59% |
 UTI Healthcare Fund-Growth Option- Direct | 21.06% | 20.93% | 28.25% | 16.3% |
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth | 20.49% | 24.07% | 31.24% | 22.61% |
 SBI Healthcare Opportunities Fund Direct Growth | 20.46% | 24.4% | 30.36% | 18.29% |
See all
Top Growth Drivers | 1M Return |
|---|---|
 Alembic Pharmaceuticals Ltd | 18.9% |
 Torrent Pharmaceuticals Ltd | 8.4% |
 Sun Pharmaceutical Industries Ltd | 8.1% |
Loading...
We are taking more time than usual
Dhaval Shah
Fund Manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth, since 11 July 2019
Top funds managed
Fund House
Aditya Birla Sun Life AMC Ltd
Total Schemes
Total AUM
₹3.76L Cr
as on 28-Feb-2025
Address
Aditya Birla Sun Life AMC Ltd,One World Centre, Tower 1, 17th Floor,Jupiter Mill Compound, 841, Senapati Bapat Marg,Elphinstone Road
Phone
+912243568000
Website
connect@birlasunlife.com
Mutual Fund Insights
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 30.95% return, outperforming this fund by 18.16%.
Over the last 1 month, this fund has increased expense ratio by 20.9% moving from 0.91 to 1.10.
Over the last 3 months, this fund has experienced a 11.7% drop in AUM moving from 854.32 Cr to 754.75 Cr.
In the last 3 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 24.07% return, outperforming this fund by 4.98% per annum.
In the last 5 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 31.24% return, outperforming this fund by 5.64% per annum.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.1% which is lower than the category average expense ratio of 1.41%.
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 22.59% since inception which is more than its category average return of 17.41%
Fund Allocations
This fund has an allocation of 98.62% in Equity, 0% in Debt and 1.39% in Cash related instruments
AUM size ₹755 Cr
This fund has AUM of ₹755 Cr which is less than its category average of ₹ 1725 Cr
Expense Ratio 1.1%
This fund has an expense ratio of 1.1% which is less than its category average expense ratio of 1.45%
Most Popular Comparisons
- Compare
Aditya Birla Sun Life Pharma & Healthcare FundVs
Nippon India Pharma Fund Direct Growth
- Compare
- Aditya Birla Sun Life Pharma & Healthcare FundVs
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
- Compare
- Aditya Birla Sun Life Pharma & Healthcare FundVs
SBI Healthcare Opportunities Fund Direct Growth
- Compare
- Aditya Birla Sun Life Pharma & Healthcare FundVs
DSP Healthcare Fund Direct Growth
- Compare
- Aditya Birla Sun Life Pharma & Healthcare FundVs
UTI Healthcare Fund Direct Growth
Frequently Asked Questions for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
The current NAV of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is ₹32.29 as on 03-Apr-2025.
Existing (Absolute + CAGR) as on 03-Apr-2025.
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 7.42% | 7.42% |
6 Month Returns | -7.72% | -7.72% |
1 Year Returns | 12.78% | 12.78% |
3 Years Returns | 68.88% | 19.09% |
5 Years Returns | 212.58% | 25.6% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
1.1% as on March 2025
₹755 Cr as on March 2025
Sun Pharmaceuticals Industries Ltd(14.49%), Cipla Ltd(8.9%), Torrent Pharmaceuticals Ltd(7.6%), Abbott India Ltd(6.56%), Apollo Hospitals Enterprise Ltd(5.93%) as on March 2025
The alpha ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | -4.9 | -0.56 | -0.55 |
As on March 2025
The alpha for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | 0.96 | 0.96 | 0.92 |
As on March 2025
The Beta for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | 0.36 | 0.74 | 1.05 |
As on March 2025
The sharpe ratio for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | 19.8 | 16.88 | 18.82 |
As on March 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.31 as on March 2025. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Dhaval Shah is the fund manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
The Exit load of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is 1%